Semax for Sale: No Package Insert, No Required Fields

Semax for sale means a product page, and a product page is marketing copy written by the seller. That sounds obvious until you compare it with what it stands in for. The label on a prescription box is not written freely: its required contents are set by federal regulation, in 21 CFR part 201 and the manufacturing rules that accompany it, which is why every prescription vial in the country carries the same fields in roughly the same places. Nothing equivalent governs a research-peptide listing. Every field on one is optional, and the ones a seller leaves out are the ones worth noticing.

So the skill this page is trying to teach is reading a listing for absences rather than claims. A vendor's claims are the part they chose to write. The fields they skipped are the part that tells you what they could not support, and there is no regulator whose job it is to notice on your behalf.

We link one supplier here and earn a commission if you buy through it, which our affiliate disclosure covers. Its listing is used below as a worked example, including on the point where a certificate stops being useful.

A prescription drug label carries an established name, the quantity of active ingredient, a national drug code, a lot number, an expiration date, and either adequate directions for use or a lawful exemption from them. Behind the box there is a manufacturer holding an approval, a batch released against a written specification, a pharmacist in the chain and a recall route if something is found later. The label is the visible end of that apparatus.

None of that exists for Semax in the United States. There is no FDA approval for any indication, no USP or National Formulary monograph setting a release specification, and no place on FDA's 503A bulks list, so no pharmacy can compound it either. The nomination history is worth stating precisely because competing pages mangle it: Semax was nominated, was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn. It appears on no current category list. Not banned, not category 2, simply absent.

The practical consequence is that the listing is not a weaker version of a label. It is a different kind of document with no mandatory content at all, and the burden of deciding what counts as adequate has moved onto the reader. Our page on the regulatory position for the neighbouring peptide works through the same absence in full detail if you want the legal reasoning rather than the shopping consequences.

One search returns semax peptide for sale, semax vials for sale and semax nasal spray for sale, which read like three phrasings of one product and are not. The fields below are where the difference becomes visible.

Form and physical state. Lyophilised powder in a sealed vial, or a pre-mixed solution in a bottle. These are different products with different risk profiles, and a listing that says only "Semax 10 mg" without saying which one is hiding the more important half. A solution has already been formulated by somebody, which is a manufacturing step nobody licensed performed.

Quantity, and against what. A stated 10 mg is a label claim. The certificate is where it either becomes a measurement or stays a claim, and the difference matters because peptide vials in this market routinely contain more or less than the number printed on them.

Batch or lot number. This is the field that makes every other field real. Without it, a certificate cannot be matched to the vial that arrives, and an unmatched certificate describes somebody else's powder. The supplier we link identifies batch 30-05260628 and publishes the document against it, which is the behaviour to look for rather than the specific number.

Storage and handling. Lyophilised peptide is comparatively tolerant of a few warm days in transit and much less tolerant of being kept warm for months. A listing that states storage conditions is telling you it has thought about the product after the sale. Most say nothing, which is also information.

Testing scope, stated exactly. Not "third-party tested", which is a phrase and not a fact. Which tests, by which method, against which acceptance limits, on which batch. A listing that names the tests is inviting you to check them, and a listing that gestures at testing in the abstract is doing the opposite.

Ranked by how much they cost you, the worst omission is the missing batch number, because it disables verification entirely. Second is a purity figure with no specification: 99 percent sounds like a pass mark until you notice nobody stated what the pass mark was, and a result without a bar to clear is a number rather than a finding. Third is the absence of identity testing, which is the difference between knowing the vial is pure and knowing what it is pure of. A perfectly pure sample of the wrong heptapeptide passes a purity test.

That last one is not hypothetical for this compound in particular. Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, the ACTH(4-7) fragment with a Pro-Gly-Pro tail, registered at PubChem CID 9811102 with a molecular weight of 813.9. Selank, the other Russian heptapeptide it shares a shelf with, is a different molecule with a different sequence and a different mass. Listings confuse the two constantly, including by describing Semax as a tuftsin analogue, which it is not. Identity confirmation by mass is what turns that from an argument into a number.

Fourth is contamination testing, and this is the omission FDA's own concern points at. The agency has said that compounded drugs containing semax may pose a risk of immunogenicity for certain routes of administration because of the potential for aggregation and peptide-related impurities, and that it lacks sufficient information to know whether the drug would cause harm if administered to humans. Its page on bulk substances that may present significant safety risks carries the wording. Aggregation and impurities are testable things. A listing that skips endotoxin and sterility has left the testable part of the agency's concern unanswered.

The supplier we link lists Semax as a 10 mg lyophilised vial and publishes a four-page combined certificate of analysis for batch 30-05260628. Open it alongside the table below rather than taking the summary on trust, because the entire point of this page is that the checking is yours to do.

Purity reports at 99.886 percent against a stated specification of greater than 98 percent, which is the correct shape for a purity claim: a result, a method, and a bar it had to clear. Bacterial endotoxin is tested by kinetic chromogenic LAL assay to USP Chapter 85 against an E. coli O111:B4 standard over a detection range of 0.01 to 1.0 EU/mL, reporting under 0.20 EU/mL against a 0.5 EU/mL acceptance limit. The microbial sterility screen reports no growth.

That combination is genuinely unusual in this market, and it belongs to a batch rather than to a product. The vendor's own February Semax certificate carries neither an endotoxin test nor a sterility screen, and its Selank listing shows the same February-to-June change. So the habit worth building is opening every certificate on a product page rather than only the one that is a clickable link. The reason to notice is not that it settles the purchase, it is that it calibrates your eye for the next seller you read.

Commercial terms, checked on the listing on 21 August 2026: $59.99 for the 10 mg vial, $30.00 with the code PEPTIDEDECK, which is $3.00 per milligram. Quantity purchases of 3, 5 or 10 take 3 percent, 5 percent or 10 percent off list separately, and free shipping starts at $250. Whether the code stacks with the tiers is undocumented, so do not plan around it.

The table below puts the fields a prescription label must carry next to what a research-peptide listing offers in their place, and what the substitute is actually worth. The right-hand column is the honest accounting.

Two rows have no substitute at all, and they are the two that matter most in the rare case where something goes wrong later. There is no recall mechanism and no human safety dossier, and no listing on the market can manufacture either one.

Open the certificate and find the batch number first. If it is not there, or it does not match the batch named on the listing, stop. Everything after that step is decoration.

Then read for specifications rather than results. Every figure should be reported against a written acceptance limit, and the tests should be named with their methods. Confirm identity is present and not just purity. For anything that will be dissolved, confirm endotoxin and a microbial screen, because those address the only part of FDA's concern that a document can address.

Then hold the last thought clearly: a certificate answers a manufacturing question and nothing more. A clean result on a batch tells you that batch was well made. It is not evidence that the substance is safe in people, which is the exact question the agency says it has insufficient information to answer, and no vendor page will draw that line for you. If you want the same field-by-field method applied elsewhere, our reads of a Selank listing and an NAD+ listing show how differently two sellers can fill the same empty form.